GLP-1 receptor agonist matches surgical levels of weight loss: trial
Phase 3 results for tirzepatide show a third of patients on 15mg weekly dose had a 25% reduction in weight
A novel anti-obesity drug could see patients lose more than a quarter of their body weight in one to two years — an amount comparable to bariatric surgery — US research reports.
Results from a phase 3 trial of tirzepatide found that one in three participants with a BMI of more than 30, but no diabetes, saw a 25% reduction in weight on a 15mg dose.
